COURSE OF POST COVID-19 DISEASE IN HEART FAILURE PATIENTS WITH MODERATELY REDUCED LEFT VENTRICULAR EJECTION FRACTION.

In this study, we assessed the impact of COVID-19 on the course of HFmrEF by determining the biomarkers furin and NT-proBNP, questionnaires (EQ-5D-5L), and cardiac ultrasound. A comprehensive examination of 72 patients with HFmrEF (main group) and 18 apparently healthy individuals (control group). The main group was divided into two subgroups depending on the history of coronavirus disease.

USE OF Β-ADRENOBLOCKERS IN PATIENTS WITH HEART FAILURE AND CONCOMITANT THYROID PATHOLOGY (LITERATURE REVIEW AND OWN OBSERVATIONS).

The systematization of literature data on the use of β-adrenoblockers in patients with heart failure and concomitant thyroid pathology was carried out, and the results of our own study were presented. It has been suggested that the final chapter in the history of the use of β-adrenoblockers in patients with heart failure with reduced left ventricular ejection fraction and thyroid pathology has not yet been written. Further studies are needed, including pharmacogenetic ones.

Use of beta-blockers in patients with heart failure - unresolved issues.

The analysis of literature data reflecting the issues of the mechanisms of action of beta-blockers in patients with heart failure are present. The heart failure has many variants. With each of these options, the concentration of catecholamines and the sensitivity of beta receptors change differently.

Damage of the cardiovascular system in lysosomal storage disease - mucopolysaccharidosis.

The analysis of literature data reflecting the issues of the pathology of the cardiovascular system in mucopolysaccharidosis are presented. It was found out that heart and vessels damage is one of the cardinal signs of this pathology, often leading to death. Cardiac pathology is recorded in all types of mucopolysaccharidosis, but it is most significant for patients with three clinical variants of Hurler syndrome, Hunter, and Maroteaux-Lamy syndromes.